6 hrs ago
Rheumatism treatment effective even when the use of biological agents is slightly delayed
The immediate use of a biological agent associated with more side effects and higher costs in the treatment of rheumatoid arthritis yields no better results than a less aggressive plan with the delayed use of biological agents where necessary.
Sun Dec 01, 2013
The Globe and Mail
Why isn't the 'gold standard' of abortion drugs available in Canada?
In Canada, there are about 100,000 abortions a year, most of them performed surgically in clinics or hospitals.
Sat Nov 30, 2013
Usability testing of ANSWER: a web-based methotrexate decision aid...
Decision aids are evidence-based tools designed to inform people of the potential benefit and harm of treatment options, clarify their preferences and provide a shared decision-making structure for discussion at a clinic visit.
Tue Nov 26, 2013
Antares Pharma Announces Additional U.S. Patent Protection for OTREXUPa
Antares Pharma, Inc. today announced the issuance of U.S. Patent 8,579,865. This new patent is related to a previously issued U.S. patent 8,480,631, and includes additional claims that describe injection devices for the subcutaneous delivery of methotrexate.
Mon Nov 25, 2013
Sun Nov 24, 2013
Sat Nov 23, 2013
Arthritis drug Sarilumab slows down the condition and improves mobility
Arthritis sufferers have been given new hope following the success of a drug that eases crippling symptoms of the disease.
Thu Nov 21, 2013
UPDATE 1-Sanofi, Regeneron arthritis drug meets goals in Phase 3 trial
An experimental drug for rheumatoid arthritis developed by French drugmaker Sanofi and Regeneron, when combined with methotrexate, improved symptoms and physical function and slowed progression of the disease in a late-stage clinical trial.
Tue Nov 19, 2013
Pfizer Inc. Wins Final FDA Approval For XELJANZ
Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZA Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis NEW YORK-- -- Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved the supplemental New Drug Application for ... (more)
Fri Nov 08, 2013
Antares: Thoughts On The Upcoming Otrexup Launch
Antares is preparing to launch Otrexup in January 2014; it is the first product it has ever introduced and investor attention is keenly focused on the launch.
Wed Nov 06, 2013
Reports from University of Michigan Highlight Recent Findings in Pharmaceutical Design
The present study investigates the validity of an alternative simplified strategy where a dual-acting molecule which bears both targeting and cytotoxic activity is conjugated to the nanoparticle as cancer-targeting nanotherapeutics."
Antares Pharma Reports Third Quarter 2013 Operating and Financial Results
Initiated a clinical study evaluating testosterone enanthate administered weekly by subcutaneous injection and dosed the first testosterone deficient adult males using the VIBEX Quick Shot auto injector device.
Tue Nov 05, 2013
Medicine treats progression, pain of rheumatoid arthritis
Dear Dr. Roach: I have had rheumatoid arthritis since 2010. I take two naproxen a day sometimes, but only one if the pain is not bad.